This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
AbbVie presented new data on its once-daily hepatitis C virus (HCV) combination, revealing high cure rates across all six major HCV genotypes.
The new phase II data on NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 – which recently started pivotal trials – showed that 97-98% of patients with genotype 1-3 HCV and no cirrhosis achieved a cure (sustained virologic response or SVR) within eight weeks of starting treatment.
Meanwhile, in patents with genotype 3 HCV and compensated cirrhosis – a notoriously hard-to-treat group – the regimen achieved 100% SVR after 12 weeks. It also achieved a 100% cure rate in patients with genotype 4-6 without cirrhosis. The data were presented at the International Liver Congress (ILC) in Barcelona, Spain, last week.
AbbVie is hoping to be able to show that ABT-493/ABT-530 can achieve high cure rates across all HCV patients with an eight-week treatment regimen, and help it claw market share in the HCV treatment category away from its main rival Gilead Sciences, which dominates the market.
Read more…http://www.pmlive.com/pharma_news/abbvie_hepatitis_c_combo_shows_high_cure_rates_995113